Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches

Executive Summary

AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel
Advertisement

Related Content

Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent
Is FDA Less Confident In ANDAs? Stay On Efudex Generic May Set Precedent
AstraZeneca Sales Force Restructuring Boosts Operating Profit, Not Sales
AstraZeneca In The “Transparency” Era: An Interview With CEO David Brennan
Generic Labeling “Carve-Outs” For Marinol Challenged On Safety Grounds
Seroquel XR approved for maintenance treatment
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups
Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
AstraZeneca Cuts 3,000 Manufacturing Jobs, Pares Down Therapeutic Areas
Advertisement
UsernamePublicRestriction

Register

PS048956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel